bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 2.63M -62.4% |
| Revenue (ttm) | 5.90M -23.2% |
| Net Income | -15.19M |
| EPS | -59.70 |
| Shares Out | 539.86K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,051 |
| Open | 4.950 |
| Previous Close | 5.060 |
| Day's Range | 4.870 - 5.170 |
| 52-Week Range | 4.870 - 202.500 |
| Beta | -1.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cance... [Read more]
Financial Performance
In 2025, bioAffinity Technologies's revenue was $6.16 million, a decrease of -34.18% compared to the previous year's $9.36 million. Losses were -$14.91 million, 64.9% more than in 2024.
Financial StatementsNews
BioAffinity Technologies files to sell 1.71M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.71M shares of common stock. The company is not selling any…
bioAffinity Technologies Registration statement: Registration filing
bioAffinity Technologies filed a registration statement on August 27, 2026, providing details about a securities offering with the SEC.
bioAffinity Technologies Inc trading halted, news pending
19:50 EDT bioAffinity Technologies (BIAF) Inc trading halted, news pending
BioAffinity Technologies announces 1-for-15 reverse stock split
bioAffinity Technologies (BIAF) announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24,…
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will effect a 1-for-15 reverse split of its common stock at the opening of trading on Nasdaq on August 24, 2026.
BioAffinity Technologies, AvMEDICAL announce distribution agreement for CyPath
bioAffinity Technologies (BIAF) announced it has entered into a distribution agreement with AvMEDICAL. The distribution agreement is expected to strengthen bioAffinity’s ability to commercialize CyPat...
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies enters distribution agreement with AvMEDICAL to expand CyPath Lung sales reach and access to government healthcare systems.
BioAffinity prices 8.46M shares at 47.27c in private placement
bioAffinity Technologies (BIAF) entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock, together with two warrants to purchase up to an ag...
BioAffinity Technologies announces closing of $4M private placement offering
BioAffinity Technologies (BIAF) announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purc...
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nas...
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces closing of $4M private placement offering.
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
JERSEY CITY, N.J., , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (N...
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces pricing of $4M private placement offering.
bioAffinity Technologies Earnings release: Q2 2026
bioAffinity Technologies released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
bioAffinity Technologies Quarterly report: Q2 2026
bioAffinity Technologies has published its Q2 2026 quarterly earnings report on August 7, 2026.
BioAffinity Technologies reports Q2 EPS (64c) vs ($5.07) last year
Reports Q2 revenue $1.5M vs $1.27M last year. “Our commercial strategy continues to gain significant traction as physicians increasingly recognize the clinical value of CyPath Lung for evaluating pati...
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reported second quarter 2026 financial results and continued commercial momentum for CyPath® Lung test for lung cancer.
BioAffinity announces publication of clinical review on CyPath Lung
bioAffinity Technologies (BIAF) announced the publication of a comprehensive clinical review and white paper authored by Chief Medical Officer Gordon Downie, MD, PhD, that presents a practical clinica...
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF publishes CyPath Lung white paper which presents clinical protocols for lung nodule evaluation, lung cancer patient care & survivor surveillance.
BioAffinity Technologies announces collaboration with Pictor
bioAffinity Technologies (BIAF) announced a collaboration with Pictor to support development and commercialization of bioAffinity Technologies’ next-generation diagnostic tests designed to provide a m...
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity and Pictor partner to advance next-generation lung inflammation diagnostics for asthma and COPD for personalized treatment.
BioAffinity Technologies’ CyPath Lung diagnostic sales double in Q2
bioAffinity Technologies (BIAF) announced continued acceleration in commercial sales for CyPath Lung, its noninvasive lung cancer diagnostic, with more than 200% growth year-over-year. The number of t...
bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year.
BioAffinity will present preclinical findings on small interfering RNAs
bioAffinity Technologies (BIAF) will present preclinical findings for a novel therapeutic approach that uses small interfering RNAs that kill squamous and basal skin cancer cells in vitro while leavin...
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells.